Two former Alexion executives, both of whom resigned in the middle of a scandal two years ago, are starting a new biotech company — one with ambitious goals in cell and gene therapy, according to a new slide deck obtained by STAT.

The presentation provides some of the first details about the secretive new company, which its founders, including David Hallal and Vikas Sinha, are calling ElevateBio. They haven’t yet publicly discussed its existence or launched a website.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I fail to see why this is newsworthy. So two guys resign from Alexion and might or might not be guilty of something (article does not make it clear) but stat decides to leak a slide deck with “confidential and proprietary” marked on every slide showing a detailed map of the lab space and offices (with potential security implications for everyone that works there).

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy